title: Effect of postremission chemotherapy before human leukocyte antigen-identical sibling transplantation for acute myelogenous leukemia in first complete remission.
abstract: Allogeneic bone marrow transplantation is an effective postremission strategy for patients with acute myelogenous leukemia (AML) in first complete remission (CR). The value of administering consolidation chemotherapy before human leukocyte antigen (HLA)-identical sibling transplantation is not established. Outcomes of patients with AML in first CR receiving no consolidation therapy, standard-dose cytarabine consolidation therapy, and high-dose cytarabine consolidation therapy before HLA-identical sibling transplantation were compared. Five-year treatment-related mortality rates were 30% (95% confidence interval [CI], 18% to 42%) in patients receiving no consolidation chemotherapy, 22% (95% CI, 17% to 28%) in those receiving standard-dose cytarabine consolidation, and 24% (95% CI, 17% to 31%) in those receiving high-dose cytarabine (P = NS). Five-year cumulative incidences of relapse were 19% (10% to 30%), 21% (16% to 27%), and 17% (11% to 24%), respectively (P = NS). Five-year probabilities of leukemia-free survival were 50% (36% to 63%), 56% (49% to 63%), and 59% (50% to 66%), respectively (P = NS). Five-year probabilities of overall survival were 60% (46% to 71%), 56% (49% to 63%), and 60% (51% to 67%), respectively (P = NS). The data indicate that postremission consolidation with cytarabine before allogeneic transplantation for AML in first CR is not associated with improved outcome compared to proceeding directly to transplantation after successful induction. (Blood. 2000;96:1254-1258)
authors.affiliation: Acute Leukemia Working Committee of the International Bone Marrow Transplant Registry, Health Policy Institute, Medical College of Wisconsin, Milwaukee, WI, USA.
authors.forename: M S
authors.initials: MS
authors.lastname: Tallman
authors.forename: P A
authors.initials: PA
authors.lastname: Rowlings
authors.forename: G
authors.initials: G
authors.lastname: Milone
authors.forename: M J
authors.initials: MJ
authors.lastname: Zhang
authors.forename: W S
authors.initials: WS
authors.lastname: Perez
authors.forename: D
authors.initials: D
authors.lastname: Weisdorf
authors.forename: A
authors.initials: A
authors.lastname: Keating
authors.forename: R P
authors.initials: RP
authors.lastname: Gale
authors.forename: R B
authors.initials: RB
authors.lastname: Geller
authors.forename: M J
authors.initials: MJ
authors.lastname: Laughlin
authors.forename: H M
authors.initials: HM
authors.lastname: Lazarus
authors.forename: S M
authors.initials: SM
authors.lastname: Luger
authors.forename: P L
authors.initials: PL
authors.lastname: McCarthy
authors.forename: J M
authors.initials: JM
authors.lastname: Rowe
authors.forename: R A
authors.initials: RA
authors.lastname: Saez
authors.forename: M R
authors.initials: MR
authors.lastname: Vowels
authors.forename: M M
authors.initials: MM
authors.lastname: Horowitz
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage*; D016026:Bone Marrow Transplantation; D003131:Combined Modality Therapy; D018572:Disease-Free Survival; D006680:HLA Antigens; D006650:Histocompatibility Testing; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000473:pathology / Q000628:therapy*; D012074:Remission Induction; D014184:Transplantation, Homologous; D016896:Treatment Outcome
chemical_list: D006680:HLA Antigens